Autolus Therapeutics Ltd Cash Flow Conversion Efficiency
Autolus Therapeutics Ltd cash flow conversion efficiency. Based on the latest financial reports, Autolus Therapeutics Ltd (AUTL) has a cash flow conversion efficiency ratio of -0.335x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.07 Million) by net assets ($74.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Autolus Therapeutics Ltd (2015–2025)
Cash flow conversion efficiency of Autolus Therapeutics Ltd from 2015 to 2025. This chart illustrates how Autolus Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Autolus Therapeutics Ltd for real-time trading data and today's change.
Autolus Therapeutics Ltd Cash Flow Conversion Ratio Explained
Autolus Therapeutics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Autolus Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Autolus Therapeutics Ltd ranked by their cash flow conversion efficiency. Also see AUTL market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Meishuo Electric Technology Co. Ltd. A
SHE:301295
|
N/A |
|
Guangzhou Hangxin Aviation Technology Co Ltd
SHE:300424
|
0.071x |
|
Shenzhen Zowee Tech Co Ltd
SHE:002369
|
-0.064x |
|
Venus Pipes & Tubes Limited
NSE:VENUSPIPES
|
0.057x |
|
Guangdong Qunxing Toys Joint-Stock Co Ltd
SHE:002575
|
0.008x |
|
Ningbo Gaofa Automotive Ctrl
SHG:603788
|
0.067x |
|
Dayang Enterprise Holdings Bhd
KLSE:5141
|
0.048x |
|
Anhui Wantong Technology Co Ltd
SHE:002331
|
-0.065x |
Annual Cash Flow Conversion Efficiency for Autolus Therapeutics Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Autolus Therapeutics Ltd from 2015 to 2025. Review AUTL FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $178.13 Million | $-283.57 Million | -1.592x | -229.79% |
| 2024-12-31 | $427.32 Million | $-206.27 Million | -0.483x | +63.04% |
| 2023-12-31 | $111.47 Million | $-145.59 Million | -1.306x | -247.32% |
| 2022-12-31 | $298.67 Million | $-112.31 Million | -0.376x | +0.04% |
| 2021-12-31 | $313.32 Million | $-117.86 Million | -0.376x | +32.91% |
| 2020-12-31 | $210.03 Million | $-117.76 Million | -0.561x | -40.79% |
| 2019-12-31 | $254.84 Million | $-101.48 Million | -0.398x | -216.06% |
| 2018-12-31 | $205.14 Million | $-25.85 Million | -0.126x | 0.00% |
| 2018-09-30 | $205.14 Million | $-25.85 Million | -0.126x | -9.83% |
| 2017-12-31 | $142.60 Million | $-16.36 Million | -0.115x | +64.25% |
| 2016-12-31 | $30.69 Million | $-9.85 Million | -0.321x | -99.85% |
| 2015-12-31 | $20.71 Million | $-3.33 Million | -0.161x | -- |
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more